Chimeric Therapeutics Limited (CHM.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.003 (+0.00%) as of
Key statistics
- Market cap
- 442.38k
- Forward P/E
- -0.05
- EPS (TTM)
- -0.6100
- Dividend yield
- 0.00%
- 52-week range
- 0.0030 – 0.4000
- Beta
- 0.88
- Revenue (TTM)
- -189.84k
- Profit margin
- 0.00%
- Volume
- 25.13M
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Carlton, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.